TY - JOUR
T1 - Sequential cyclic combined hormonal therapy for metastatic breast cancer
AU - Hortobagyi, Gabriel N.
AU - Hug, Verena
AU - Buzdar, Aman U.
AU - Kau, Shu W.
AU - Holmes, Frankie A.
AU - Fritsche, Herbert A.
PY - 1989/9/1
Y1 - 1989/9/1
N2 - Thirty postmenopausal patients who had evaluable estrogen receptor‐positive or unknown metastatic breast cancer were treated with cyclic sequential combined hormonal therapy consisting of 50 μg of ethinylestradiol orally daily for 7 days followed by 400 mg of medroxyprogesterone acetate orally daily for 21 days, followed in turn by 7 days of rest. Cyclic administration was continued until progressive disease was detected. Patients who had had one previous chemotherapy regimen were included, but 63% of patients were previously untreated. Six patients achieved complete remission and 11, a partial remission, for an overall response rate of 57%. Median remission duration was 22 months; median time to disease progression for all 30 patients was 8 months. Toxicity consisted of cyclic vaginal bleeding, hot flashes, weight gain, irritability, and fluid retention. This cyclic, sequential hormonal regimen was effective and well tolerated.
AB - Thirty postmenopausal patients who had evaluable estrogen receptor‐positive or unknown metastatic breast cancer were treated with cyclic sequential combined hormonal therapy consisting of 50 μg of ethinylestradiol orally daily for 7 days followed by 400 mg of medroxyprogesterone acetate orally daily for 21 days, followed in turn by 7 days of rest. Cyclic administration was continued until progressive disease was detected. Patients who had had one previous chemotherapy regimen were included, but 63% of patients were previously untreated. Six patients achieved complete remission and 11, a partial remission, for an overall response rate of 57%. Median remission duration was 22 months; median time to disease progression for all 30 patients was 8 months. Toxicity consisted of cyclic vaginal bleeding, hot flashes, weight gain, irritability, and fluid retention. This cyclic, sequential hormonal regimen was effective and well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=0024411390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024411390&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19890901)64:5<1002::AID-CNCR2820640505>3.0.CO;2-B
DO - 10.1002/1097-0142(19890901)64:5<1002::AID-CNCR2820640505>3.0.CO;2-B
M3 - Article
C2 - 2527085
AN - SCOPUS:0024411390
SN - 0008-543X
VL - 64
SP - 1002
EP - 1006
JO - Cancer
JF - Cancer
IS - 5
ER -